BioCentury
ARTICLE | Clinical News

Sodium oxybate: Development discontinued

May 9, 2011 7:00 AM UTC

Jazz disclosed in its 1Q11 financial results that it will not conduct the additional trials of sodium oxybate that FDA requested in its October 2010 complete response letter for the fibromyalgia candi...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article